Grofibrat S

Grofibrat S is a prescription oral medication that contains the micronised form of fenofibrate as its active ingredient. It is marketed in the European Union and is supplied as tablets (or unspecified form). Fenofibrate belongs to the fibrate class of lipid‑lowering agents and works by activating PPARα to help reduce triglyceride and cholesterol levels. The product is intended for use under medical and clinical supervision.

Grofibrat S is indicated for the management of several lipid disorders, typically when diet and lifestyle changes alone are insufficient.

- Primary treatment of hypertriglyceridemia to lower elevated triglyceride levels. - Adjunct therapy for mixed dyslipidemia, addressing high triglycerides and low HDL‑cholesterol. - Used together with statins for patients with hypercholesterolemia who need additional triglyceride reduction. - May be prescribed for patients with familial combined hyperlipidemia when other agents are inadequate. - Helps reduce the risk of pancreatitis associated with severe hypertriglyceridemia.

The safety profile of Grofibrat S includes both frequently observed and less common adverse reactions that may require medical attention.

Common: - Gastrointestinal discomfort such as abdominal pain, nausea, dyspepsia, or loose stools, which are usually mild and transient. - Muscle aches, tenderness, or weakness, particularly when the drug is used together with a statin. - Mild elevations in liver enzymes (ALT/AST) indicating temporary hepatic stress. - Headache, dizziness, or fatigue that may improve with continued therapy.

Serious: - Rhabdomyolysis, a rare but severe breakdown of muscle tissue that can lead to myoglobinuria and acute kidney injury. - Acute liver injury presenting with jaundice, marked enzyme elevation, or hepatic failure, requiring immediate medical evaluation. - Severe hypersensitivity reactions such as rash, pruritus, angio‑edema, or anaphylaxis.

Before prescribing Grofibrat S, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

- Assess liver function; avoid in active hepatic disease or unexplained persistent transaminase elevations. - Evaluate renal function; dose adjustment may be required in moderate to severe impairment. - Review concomitant drugs that increase myopathy risk, especially statins or gemfibrozil. - Avoid use in pregnancy and lactation unless benefits outweigh risks, as safety data are limited. - Monitor lipid profile and liver enzymes periodically during treatment. - Caution in patients with a history of gallstones, as fenofibrate may promote biliary sludge formation.

Grofibrat S can interact with several medicines, influencing its efficacy or increasing the risk of adverse effects.

Avoid: - Gemfibrozil, because combined use markedly raises the risk of myopathy and rhabdomyolysis. - High-dose statins (e.g., simvastatin >40 mg) when used together may increase muscle toxicity. - Cyclosporine, which can raise fenofibrate plasma concentrations. - Concomitant use with cholestyramine or colestipol may reduce fenofibrate absorption, decreasing its lipid‑lowering effect.

Use with caution: - Anticoagulants (warfarin) – fenofibrate may enhance anticoagulant effect, requiring INR monitoring. - Oral hypoglycemic agents – fenofibrate can potentiate glucose‑lowering, risking hypoglycemia. - Thyroid hormone replacement – may alter thyroid hormone levels, necessitating dose adjustment. - Protease inhibitors – may increase fenofibrate levels, so monitor for toxicity.